We feel now is a pretty good time to analyse Trulieve Cannabis Corp.'s (NYSE:TRLV) business as it appears the company may be on the cusp of a considerable accomplishment. Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The US$3.1b market-cap company’s loss lessened since it announced a US$111m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$76m, as it approaches breakeven. As path to profitability is the topic on Trulieve Cannabis' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts’ expectations for the company.

Consensus from 7 of the American Pharmaceuticals analysts is that Trulieve Cannabis is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$58m in 2026. The company is therefore projected to breakeven around 12 months from now or less. At what rate will the company have to grow in order to realise the consensus estimates forecasting breakeven in under 12 months? Using a line of best fit, we calculated an average annual growth rate of 125%, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Underlying developments driving Trulieve Cannabis' growth isn’t the focus of this broad overview, however, take into account that generally pharmaceuticals, depending on the stage of product development, have irregular periods of cash flow. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before we wrap up, there’s one aspect worth mentioning. The company has managed its capital prudently, with debt making up 25% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of Trulieve Cannabis which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Trulieve Cannabis, take a look at Trulieve Cannabis' company page on Simply Wall St. We've also compiled a list of essential aspects you should further research:

1. Valuation: What is Trulieve Cannabis worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Trulieve Cannabis is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Trulieve Cannabis’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.